Researchers performed a double-blind trial at a tertiary care hospital in India. Patients with cirrhosis who had recovered from an episode of hepatic encephalopathy during the previous month were assigned randomly to groups given a probiotic preparation or placebo daily for six months.
The study found a reduction in the development of breakthrough hepatic encephalopathy among patients receiving the probiotic — 34.8 percent in the probiotic group versus 51.6 percent in the placebo group. Also, fewer patients in the probiotic group were hospitalized for hepatic encephalopathy, 19.7 percent, as compared to 42.2 percent in the placebo group. Only 24.2 percent of patients in the probiotic group were hospitalized for complications of cirrhosis.
More articles on gastroenterology:
Cantel Medical names Jorgen Hansen president, COO
Hanover Gastroenterology expands
GI physician to know: Dr. David Rubin of University of Chicago Medicine
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
